Roferon-A

Roferon-A

a trademark for a parenteral antineoplastic (interferon-alfa-2a).

Roferon-A

A brand name for INTERFERON ALFA-2a.
References in periodicals archive ?
Roche is committed to the viral hepatitis disease area, having introduced Roferon-A for hepatitis B and C, followed by PEGASYS in hepatitis C and a full development program in hepatitis B.
Roferon-A - licensed only last month - is the first approved treatment for advanced skin cancer.
Roche is committed to the viral hepatitis disease area, having first introduced Roferon-A for hepatitis B and then C, followed by PEGASYS in hepatitis C.
The market is currently driven by the use of the following immunomodulating agents: Schering-Plough's Intron A (interferon [IFN] alpha-2b), Roche's Roferon-A (IFN alpha-2a) and Novartis' Proleukin (aldesleukin); with new market entrants Bayer/Onyx Pharmaceuticals' Nexavar (sorafenib) and Pfizer's Sutent (sunitinib) making significant inroads into the market in 2006, their first year of sales.
Roche is committed to the viral hepatitis disease area, having introduced Roferon-A for hepatitis B and C, followed by PEGASYS in hepatitis C and now PEGASYS is demonstrating similar superior efficacy over conventional interferon in hepatitis B.
In the Phase III study, Pegasys was administered once weekly at a dose of 180 mcg for 48 weeks, while Roferon-A was administered thrice weekly for 12 weeks at a dose of 6 million units followed by 3 million units for 36 weeks (the so-called induction regimen).
The Roche oncology portfolio also includes NeoRecormon (anaemia in various cancer settings), Bondronat (prevention of skeletal events in breast cancer and bone metastases patients, hypercalcaemia of malignancy), Kytril (chemotherapy and radiotherapy-induced nausea and vomiting) and Roferon-A (hairy cell and chronic myeloid leukaemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma).
Other key products include NeoRecormon (anaemia in various cancer settings), Bondronat (prevention of skeletal events in breast cancer and bone metastases patients, hypercalcemia of malignancy), Kytril (chemotherapy and radiotherapy-induced nausea and vomiting) and Roferon-A (leukaemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma).
Roferon-A currently is available in the United States for the treatment of several types of cancer, including hairy-cell leukemia, AIDS-related Kaposi's sarcoma, and pH-positive chronic myelogenous leukemia.
Roferon-A is also in development as a treatment for hepatitis C and malignant melanoma.
Roche markets alpha interferon in the United States under the trademark Roferon-A (interferon alfa-2a, recombinant) for the treatment of hairy cell leukemia, AIDS-related Kaposi's sarcoma and chronic myelogenous leukemia.